Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition

Hiroyuki Yamamoto, Bruno Ramos-Molina, Adam N. Lick, Matthew Prideaux, Valeria Albornoz, Lynda Bonewald, Iris Lindberg

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

FGF23 is an O-glycosylated circulating peptide hormone with a critical role in phosphate homeostasis; it is inactivated by cellular proprotein convertases in a pre-release degradative pathway. We have here examined the metabolism of FGF23 in a model bone cell line, IDG-SW3, prior to and following differentiation, as well as in regulated secretory cells. Labeling experiments showed that the majority of 35S-labeled FGF23 was cleaved to smaller fragments which were constitutively secreted by all cell types. Intact FGF23 was much more efficiently stored in differentiated than in undifferentiated IDG-SW3 cells. The prohormone convertase PC2 has recently been implicated in FGF23 degradation; however, FGF23 was not targeted to forskolin-stimulatable secretory vesicles in a regulated cell line, suggesting that it lacks a targeting signal to PC2-containing compartments. In vitro, PC1/3 and PC2, but not furin, efficiently cleaved glycosylated FGF23; surprisingly, PC5/6 accomplished a small amount of conversion. FGF23 has recently been shown to be phosphorylated by the kinase FAM20C, a process which was shown to reduce FGF23 glycosylation and promote its cleavage; our in vitro data, however, show that phosphorylation does not directly impact cleavage, as both PC5/6 and furin were able to efficiently cleave unglycosylated, phosphorylated FGF23. Using qPCR, we found that the expression of FGF23 and PC5/6, but not PC2 or furin, increased substantially following osteoblast to osteocyte differentiation. Western blotting confirmed the large increase in PC5/6 expression upon differentiation. FGF23 has been linked to a variety of bone disorders ranging from autosomal dominant hypophosphatemic rickets to chronic kidney disease. A better understanding of the biosynthetic pathway of this hormone may lead to new treatments for these diseases.

Original languageEnglish (US)
Pages (from-to)120-130
Number of pages11
JournalBone
Volume84
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Osteocytes
Furin
Osteoblasts
Proprotein Convertase 2
Proprotein Convertases
Bone and Bones
Cell Line
Peptide Hormones
Biosynthetic Pathways
Secretory Vesicles
Colforsin
Chronic Renal Insufficiency
Glycosylation
Homeostasis
Phosphotransferases
Western Blotting
Phosphates
Phosphorylation
Hormones
tetrapeptide carbamate

Keywords

  • 7B2
  • FGF23
  • Furin
  • Osteocyte
  • PC5/6
  • Posttranslational processing
  • Proprotein convertase

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Histology
  • Physiology

Cite this

Yamamoto, H., Ramos-Molina, B., Lick, A. N., Prideaux, M., Albornoz, V., Bonewald, L., & Lindberg, I. (2016). Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. Bone, 84, 120-130. https://doi.org/10.1016/j.bone.2015.12.055

Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. / Yamamoto, Hiroyuki; Ramos-Molina, Bruno; Lick, Adam N.; Prideaux, Matthew; Albornoz, Valeria; Bonewald, Lynda; Lindberg, Iris.

In: Bone, Vol. 84, 01.03.2016, p. 120-130.

Research output: Contribution to journalArticle

Yamamoto, H, Ramos-Molina, B, Lick, AN, Prideaux, M, Albornoz, V, Bonewald, L & Lindberg, I 2016, 'Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition', Bone, vol. 84, pp. 120-130. https://doi.org/10.1016/j.bone.2015.12.055
Yamamoto, Hiroyuki ; Ramos-Molina, Bruno ; Lick, Adam N. ; Prideaux, Matthew ; Albornoz, Valeria ; Bonewald, Lynda ; Lindberg, Iris. / Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. In: Bone. 2016 ; Vol. 84. pp. 120-130.
@article{6ad5c3558ad04ac5b80bcb2ba2f158de,
title = "Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition",
abstract = "FGF23 is an O-glycosylated circulating peptide hormone with a critical role in phosphate homeostasis; it is inactivated by cellular proprotein convertases in a pre-release degradative pathway. We have here examined the metabolism of FGF23 in a model bone cell line, IDG-SW3, prior to and following differentiation, as well as in regulated secretory cells. Labeling experiments showed that the majority of 35S-labeled FGF23 was cleaved to smaller fragments which were constitutively secreted by all cell types. Intact FGF23 was much more efficiently stored in differentiated than in undifferentiated IDG-SW3 cells. The prohormone convertase PC2 has recently been implicated in FGF23 degradation; however, FGF23 was not targeted to forskolin-stimulatable secretory vesicles in a regulated cell line, suggesting that it lacks a targeting signal to PC2-containing compartments. In vitro, PC1/3 and PC2, but not furin, efficiently cleaved glycosylated FGF23; surprisingly, PC5/6 accomplished a small amount of conversion. FGF23 has recently been shown to be phosphorylated by the kinase FAM20C, a process which was shown to reduce FGF23 glycosylation and promote its cleavage; our in vitro data, however, show that phosphorylation does not directly impact cleavage, as both PC5/6 and furin were able to efficiently cleave unglycosylated, phosphorylated FGF23. Using qPCR, we found that the expression of FGF23 and PC5/6, but not PC2 or furin, increased substantially following osteoblast to osteocyte differentiation. Western blotting confirmed the large increase in PC5/6 expression upon differentiation. FGF23 has been linked to a variety of bone disorders ranging from autosomal dominant hypophosphatemic rickets to chronic kidney disease. A better understanding of the biosynthetic pathway of this hormone may lead to new treatments for these diseases.",
keywords = "7B2, FGF23, Furin, Osteocyte, PC5/6, Posttranslational processing, Proprotein convertase",
author = "Hiroyuki Yamamoto and Bruno Ramos-Molina and Lick, {Adam N.} and Matthew Prideaux and Valeria Albornoz and Lynda Bonewald and Iris Lindberg",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.bone.2015.12.055",
language = "English (US)",
volume = "84",
pages = "120--130",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition

AU - Yamamoto, Hiroyuki

AU - Ramos-Molina, Bruno

AU - Lick, Adam N.

AU - Prideaux, Matthew

AU - Albornoz, Valeria

AU - Bonewald, Lynda

AU - Lindberg, Iris

PY - 2016/3/1

Y1 - 2016/3/1

N2 - FGF23 is an O-glycosylated circulating peptide hormone with a critical role in phosphate homeostasis; it is inactivated by cellular proprotein convertases in a pre-release degradative pathway. We have here examined the metabolism of FGF23 in a model bone cell line, IDG-SW3, prior to and following differentiation, as well as in regulated secretory cells. Labeling experiments showed that the majority of 35S-labeled FGF23 was cleaved to smaller fragments which were constitutively secreted by all cell types. Intact FGF23 was much more efficiently stored in differentiated than in undifferentiated IDG-SW3 cells. The prohormone convertase PC2 has recently been implicated in FGF23 degradation; however, FGF23 was not targeted to forskolin-stimulatable secretory vesicles in a regulated cell line, suggesting that it lacks a targeting signal to PC2-containing compartments. In vitro, PC1/3 and PC2, but not furin, efficiently cleaved glycosylated FGF23; surprisingly, PC5/6 accomplished a small amount of conversion. FGF23 has recently been shown to be phosphorylated by the kinase FAM20C, a process which was shown to reduce FGF23 glycosylation and promote its cleavage; our in vitro data, however, show that phosphorylation does not directly impact cleavage, as both PC5/6 and furin were able to efficiently cleave unglycosylated, phosphorylated FGF23. Using qPCR, we found that the expression of FGF23 and PC5/6, but not PC2 or furin, increased substantially following osteoblast to osteocyte differentiation. Western blotting confirmed the large increase in PC5/6 expression upon differentiation. FGF23 has been linked to a variety of bone disorders ranging from autosomal dominant hypophosphatemic rickets to chronic kidney disease. A better understanding of the biosynthetic pathway of this hormone may lead to new treatments for these diseases.

AB - FGF23 is an O-glycosylated circulating peptide hormone with a critical role in phosphate homeostasis; it is inactivated by cellular proprotein convertases in a pre-release degradative pathway. We have here examined the metabolism of FGF23 in a model bone cell line, IDG-SW3, prior to and following differentiation, as well as in regulated secretory cells. Labeling experiments showed that the majority of 35S-labeled FGF23 was cleaved to smaller fragments which were constitutively secreted by all cell types. Intact FGF23 was much more efficiently stored in differentiated than in undifferentiated IDG-SW3 cells. The prohormone convertase PC2 has recently been implicated in FGF23 degradation; however, FGF23 was not targeted to forskolin-stimulatable secretory vesicles in a regulated cell line, suggesting that it lacks a targeting signal to PC2-containing compartments. In vitro, PC1/3 and PC2, but not furin, efficiently cleaved glycosylated FGF23; surprisingly, PC5/6 accomplished a small amount of conversion. FGF23 has recently been shown to be phosphorylated by the kinase FAM20C, a process which was shown to reduce FGF23 glycosylation and promote its cleavage; our in vitro data, however, show that phosphorylation does not directly impact cleavage, as both PC5/6 and furin were able to efficiently cleave unglycosylated, phosphorylated FGF23. Using qPCR, we found that the expression of FGF23 and PC5/6, but not PC2 or furin, increased substantially following osteoblast to osteocyte differentiation. Western blotting confirmed the large increase in PC5/6 expression upon differentiation. FGF23 has been linked to a variety of bone disorders ranging from autosomal dominant hypophosphatemic rickets to chronic kidney disease. A better understanding of the biosynthetic pathway of this hormone may lead to new treatments for these diseases.

KW - 7B2

KW - FGF23

KW - Furin

KW - Osteocyte

KW - PC5/6

KW - Posttranslational processing

KW - Proprotein convertase

UR - http://www.scopus.com/inward/record.url?scp=84953377174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953377174&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2015.12.055

DO - 10.1016/j.bone.2015.12.055

M3 - Article

C2 - 26746780

AN - SCOPUS:84953377174

VL - 84

SP - 120

EP - 130

JO - Bone

JF - Bone

SN - 8756-3282

ER -